Nabriva Therapeutics (NBRV) Reaches New 52-Week High and Low at $4.22

Nabriva Therapeutics PLC – (NASDAQ:NBRV) shares hit a new 52-week high and low during trading on Thursday . The company traded as low as $4.22 and last traded at $4.28, with a volume of 8238 shares changing hands. The stock had previously closed at $4.39.

A number of research analysts recently commented on NBRV shares. Bank of America upped their price target on shares of Nabriva Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, May 22nd. Cantor Fitzgerald set a $16.00 price target on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research note on Monday, May 21st. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Nabriva Therapeutics in a research note on Tuesday, May 8th. ValuEngine upgraded shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Nabriva Therapeutics has an average rating of “Buy” and a consensus target price of $16.81.

The stock has a market capitalization of $160.45 million, a PE ratio of -1.74 and a beta of 1.74.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative net margin of 600.34% and a negative return on equity of 79.30%. The firm had revenue of $7.55 million for the quarter, compared to analyst estimates of $1.27 million. equities research analysts expect that Nabriva Therapeutics PLC – will post -1.82 earnings per share for the current year.

In other Nabriva Therapeutics news, General Counsel Robert Crotty bought 10,000 shares of the firm’s stock in a transaction on Wednesday, May 23rd. The shares were purchased at an average price of $4.48 per share, for a total transaction of $44,800.00. Following the transaction, the general counsel now directly owns 10,000 shares in the company, valued at approximately $44,800. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Stephen W. Webster bought 8,000 shares of the firm’s stock in a transaction on Wednesday, May 23rd. The shares were acquired at an average price of $4.59 per share, for a total transaction of $36,720.00. Following the transaction, the director now owns 8,000 shares in the company, valued at $36,720. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 22,160 shares of company stock worth $100,596. Company insiders own 2.75% of the company’s stock.

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of Nabriva Therapeutics by 163.9% during the 1st quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 15,501 shares in the last quarter. DRW Securities LLC bought a new stake in shares of Nabriva Therapeutics during the 1st quarter worth approximately $106,000. Stanley Laman Group Ltd. bought a new stake in shares of Nabriva Therapeutics during the 4th quarter worth approximately $154,000. Trexquant Investment LP bought a new stake in shares of Nabriva Therapeutics during the 1st quarter worth approximately $244,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Nabriva Therapeutics by 173.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 70,917 shares during the period. Hedge funds and other institutional investors own 68.88% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply